AzurRx BioPharma Will Conduct Phase 2b Trial of MS1819 at TDN Clinical Sites
AzurRx BioPharma has been authorized to conduct its Phase 2b OPTION 2 clinical trial evaluating MS1819, its investigative therapy for...


Safety, Early Effectiveness of POL6014 Confirmed in Phase 1 Trial
Single dosing of orally inhaled POL6014, an experimental therapy to treat chronic lung inflammation, can effectively block the activity...


Trial of Nebulized CF Candidate Therapy Completes Single-ascending Dosing
The RESTORE-CF clinical trial investigating Translate Bio’s candidate therapy MRT5005 has completed the single-ascending dose regimen in...


WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials
The World Health Organization (WHO) approved ensifentrine as the recommended name to identify the cystic fibrosis (CF) treatment...


Phase 3 Trial of RDEB Therapy EB-101 to Start in 2019, Abeona Therapeutics Says
Abeona Therapeutics plans to start a Phase 3 trial in 2019 testing the cell therapy candidate EB-101 as a treatment for recessive...


MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial
AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential...


Sound Pharmaceuticals to present initial data on the STOP Ototoxicity Study at Cystic Fibrosis Confe
Sound Pharmaceuticals (SPI) is pleased to announce that its recent submission to the upcoming North American Cystic Fibrosis Conference...

Supplemental antioxidants may reduce exacerbations in cystic fibrosis
An antioxidant-enriched vitamin may decrease respiratory exacerbations in people with cystic fibrosis (CF), according to new research...


Galapagos to Start Trial Testing New Triple-Combo Therapy for CF
Galapagos is starting a clinical trial called FALCON to evaluate a new triple-combination therapy to treat cystic fibrosis patients. The...


Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Pati
RPL554 demonstrates a favorable pharmacokinetic and pharmacodynamic profile in cystic fibrosis patients LONDON, UK I March 02, 2018 I...